

Wright Medical Group N.V.
Reconciliation of Non-GAAP Combined Organic and Pro Forma Net Sales to Net Sales
(dollars in thousands--unaudited)

	Three months ended March 31, 2019		
	Legacy Wright (organic)	Standalone Cartiva	Wright Medical Group N.V.
U.S.			
Lower extremities	\$ 62,863	\$ 8,445	\$ 71,308
Upper extremities	81,727	—	81,727
Biologics	22,640	—	22,640
Sports med & other	2,092	—	2,092
Total U.S.	\$ 169,322	\$ 8,445	\$ 177,767
International			
Lower extremities	\$ 14,760	\$ 791	\$ 15,551
Upper extremities	29,465	—	29,465
Biologics	4,538	—	4,538
Sports med & other	2,806	—	2,806
Total International	\$ 51,569	\$ 791	\$ 52,360
Global			
Lower extremities	\$ 77,623	\$ 9,236	\$ 86,859
Upper extremities	111,192	—	111,192
Biologics	27,178	—	27,178
Sports med & other	4,898	—	4,898
Total net sales	\$ 220,891	\$ 9,236	\$ 230,127

Three months ended April 1, 2018

	Standalone Wright Medical Group N.V.	Standalone Cartiva	Non-GAAP combined pro forma
U.S.			
Lower extremities	\$ 56,823	\$ 8,611	\$ 65,434
Upper extremities	67,658	—	67,658
Biologics	18,165	—	18,165
Sports med & other	2,147	—	2,147
Total U.S.	\$ 144,793	\$ 8,611	\$ 153,404
International			
Lower extremities	\$ 15,327	\$ 296	\$ 15,623
Upper extremities	29,594	—	29,594
Biologics	5,257	—	5,257
Sports med & other	3,566	—	3,566
Total International	\$ 53,744	\$ 296	\$ 54,040
Global			
Lower extremities	\$ 72,150	\$ 8,907	\$ 81,057
Upper extremities	97,252	—	97,252
Biologics	23,422	—	23,422
Sports med & other	5,713	—	5,713
Total net sales	\$ 198,537	\$ 8,907	\$ 207,444

**Non-GAAP organic and combined pro forma constant
currency net sales growth/(decline)**

	Legacy Wright (organic) constant currency	Standalone Cartiva	Non-GAAP combined pro forma constant currency
U.S.			
Lower extremities	10.6%	N/A	9.0%
Upper extremities	20.8%	N/A	20.8%
Biologics	24.6%	N/A	24.6%
Sports med & other	(2.6)%	N/A	(2.6)%
Total U.S.	16.9%	N/A	15.9%
International			
Lower extremities	2.8%	N/A	5.9%
Upper extremities	7.1%	N/A	7.1%
Biologics	(8.8)%	N/A	(8.8)%
Sports med & other	(15.3)%	N/A	(15.3)%
Total International	2.8%	N/A	3.7%
Global			
Lower extremities	9.0%	N/A	8.4%
Upper extremities	16.6%	N/A	16.6%
Biologics	17.1%	N/A	17.1%
Sports med & other	(10.6)%	N/A	(10.3)%
Total net sales	13.1%	N/A	12.7%

Wright Medical Group N.V.
Supplemental Net Sales Information
(unaudited)

Three months ended March 31, 2019 net sales growth/(decline)

Product line	U.S. as reported	Int'l constant currency	Int'l as reported	Global constant currency	Global as reported
Lower extremities	25%	8%	1%	22%	20%
Upper extremities	21%	7%	0%	17%	14%
Biologics ¹	25%	(9%)	(14%)	17%	16%
Sports med & other	(3%)	(15%)	(21%)	(11%)	(14%)
Total net sales	23%	4%	(3%)	18%	16%

¹ The US biologics growth rate includes an approximate 5 percentage point benefit from a bulk sale of the PDGF raw material. [25% US as reported growth – 5% impact of PDGF bulk sale = 20% growth rate excluding this benefit]

Wright Medical Group N.V.

Reconciliation of Adjusted Non-GAAP Earnings Per Share to Net Loss from Continuing Operations Per Share

(dollars in thousands, except per share data--unaudited)

	Three months ended	
	March 31, 2019	April 1, 2018
Net loss from continuing operations, as reported	\$ (30,256)	\$ (19,907)
Weighted-average diluted shares outstanding	125,812	105,904
Net loss from continuing operations per share, as reported	\$ (0.24)	\$ (0.19)
Reconciling items:		
Non-cash interest expense on convertible notes ¹	12,265	12,012
Net charges on debt modification ²	14,274	—
Derivatives mark-to-market adjustments ²	(996)	1,694
Inventory step-up amortization	352	—
Transition costs	424	910
Foreign currency translation expense ²	(300)	763
CVR mark-to-market adjustments ²	(420)	(3,924)
Contingent consideration fair value adjustment ²	376	414
Tax expense due to change in tax rates on income from deferred intercompany transactions ³	2,566	—
Tax effect of reconciling items ⁴	(5)	(210)
Non-GAAP net loss from continuing operations, as adjusted	\$ (1,720)	\$ (8,248)
Add back amortization of intangible assets	7,587	7,141
Adjusted non-GAAP earnings	\$ 5,867	\$ (1,107)
Adjusted non-GAAP weighted-average diluted shares outstanding ⁵	129,042	105,904
Adjusted non-GAAP earnings per share	\$ 0.05	\$ (0.01)

¹ Impacting interest expense, net.

² Impacting other expense (income), net.

³ Impacting provision from income taxes.

⁴ Determined based upon the effective tax rate in the jurisdiction in which the expense was incurred.

⁵ Adjusted non-GAAP weighted-average diluted shares outstanding includes common stock equivalents of 3.2 million for the three months ended March 31, 2019, based on the income position of our adjusted non-GAAP earnings.

Wright Medical Group N.V.
Reconciliation of Non-GAAP Adjusted EBITDA to Net Loss from Continuing Operations
(dollars in thousands--unaudited)

	Three months ended	
	March 31, 2019	April 1, 2018
Net loss from continuing operations	\$ (30,256)	\$ (19,907)
Interest expense, net	19,695	19,812
Provision from income taxes	3,611	205
Depreciation	15,501	14,499
Amortization	7,587	7,141
Non-GAAP EBITDA	\$ 16,138	\$ 21,750
Reconciling items impacting EBITDA:		
Non-cash share-based compensation expense	7,621	5,018
Other expense (income), net	12,895	(1,000)
Inventory step-up amortization	352	—
Transition costs	424	910
Non-GAAP adjusted EBITDA	\$ 37,430	\$ 26,678
Net sales from continuing operations	230,127	198,537
Non-GAAP adjusted EBITDA margin	16.3%	13.4%

Wright Medical Group N.V.
Reconciliation of Non-GAAP Adjusted Gross Margins to Gross Margins from Continuing Operations
(dollars in thousands--unaudited)

	Three months ended	
	March 31, 2019	April 1, 2018
Gross profit from continuing operations, as reported	\$ 183,810	\$ 157,398
Gross margins from continuing operations, as reported	79.9 %	79.3 %
Reconciling items impacting gross profit:		
Inventory step-up amortization	352	—
Transition costs	—	910
Non-GAAP gross profit from continuing operations, as adjusted	\$ 184,162	\$ 158,308
Net sales from continuing operations	230,127	198,537
Non-GAAP adjusted gross margins from continuing operations	80.0%	79.7%

Wright Medical Group N.V.
Reconciliation of Other Non-GAAP Financial Measures to Other As Reported Results
(dollars in thousands--unaudited)

	Three months ended	
	March 31, 2019	April 1, 2018
Net sales	\$ 230,127	\$ 198,537
Selling, general and administrative expense, as reported	\$ 153,306	\$ 137,248
Selling, general and administrative expense as a percentage of net sales, as reported	66.6 %	69.1 %
Reconciling items impacting selling, general and administrative expense:		
Transition costs	424	—
Selling, general and administrative expense, as adjusted	\$ 152,882	\$ 137,248
Selling, general and administrative expense as a percentage of net sales, as adjusted	66.4%	69.1%